First Header Logo Second Header Logo

Connection

Pierre Triozzi to Humans

Back to Details
This is a "connection" page, showing publications Pierre Triozzi has written about Humans.
Pierre Triozzi
Connection Strength
0.724
Humans
  1. Joshi P, Kooshki M, Aldrich W, Varghai D, Zborowski M, Singh AD, Triozzi PL. Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells. Clin Exp Metastasis. 2016 12; 33(8):829-838.
    View in: PubMed
    Score: 0.030
  2. Triozzi PL, Achberger S, Aldrich W, Crabb JW, Saunthararajah Y, Singh AD. Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma. Clin Epigenetics. 2016; 8:80.
    View in: PubMed
    Score: 0.030
  3. Triozzi PL, Aldrich W, Crabb JW, Singh AD. Spontaneous cellular and humoral tumor antigen responses in patients with uveal melanoma. Melanoma Res. 2015 Dec; 25(6):510-8.
    View in: PubMed
    Score: 0.028
  4. Singh AD, Medina CA, Singh N, Aronow ME, Biscotti CV, Triozzi PL. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br J Ophthalmol. 2016 Apr; 100(4):456-62.
    View in: PubMed
    Score: 0.028
  5. Achberger S, Aldrich W, Tubbs R, Crabb JW, Singh AD, Triozzi PL. Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol Immunol. 2014 Apr; 58(2):182-6.
    View in: PubMed
    Score: 0.025
  6. Brenner AJ, Cohen YC, Breitbart E, Bangio L, Sarantopoulos J, Giles FJ, Borden EC, Harats D, Triozzi PL. Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors. Clin Cancer Res. 2013 Jul 15; 19(14):3996-4007.
    View in: PubMed
    Score: 0.024
  7. Triozzi PL, Elson P, Aldrich W, Achberger S, Tubbs R, Biscotti CV, Singh AD. Elevated blood ß-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma. Melanoma Res. 2013 Feb; 23(1):1-7.
    View in: PubMed
    Score: 0.023
  8. Triozzi PL, Achberger S, Aldrich W, Singh AD, Grane R, Borden EC. The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon. J Transl Med. 2012 Dec 05; 10:241.
    View in: PubMed
    Score: 0.023
  9. Triozzi PL, Achberger S, Aldrich W, Elson P, Garcia J, Dreicer R. Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte/macrophage colony stimulating factor. J Immunother. 2012 Sep; 35(7):587-94.
    View in: PubMed
    Score: 0.023
  10. Triozzi PL, Aldrich W, Achberger S, Ponnazhagan S, Alcazar O, Saunthararajah Y. Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice. Cancer Immunol Immunother. 2012 Sep; 61(9):1441-50.
    View in: PubMed
    Score: 0.022
  11. Triozzi PL, Singh AD. Blood biomarkers for uveal melanoma. Future Oncol. 2012 Feb; 8(2):205-15.
    View in: PubMed
    Score: 0.022
  12. Triozzi PL, Borden EC. VB-111 for cancer. Expert Opin Biol Ther. 2011 Dec; 11(12):1669-76.
    View in: PubMed
    Score: 0.021
  13. Alcazar O, Achberger S, Aldrich W, Hu Z, Negrotto S, Saunthararajah Y, Triozzi P. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer. 2012 Jul 01; 131(1):18-29.
    View in: PubMed
    Score: 0.021
  14. Triozzi PL, Aldrich W, Singh A. Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma. Invest Ophthalmol Vis Sci. 2011 Jul 25; 52(8):5529-35.
    View in: PubMed
    Score: 0.021
  15. Triozzi PL, Tuthill RJ, Borden E. Re-inventing intratumoral immunotherapy for melanoma. Immunotherapy. 2011 May; 3(5):653-71.
    View in: PubMed
    Score: 0.021
  16. Borden EC, Jacobs B, Hollovary E, Rybicki L, Elson P, Olencki T, Triozzi P. Gene regulatory and clinical effects of interferon ß in patients with metastatic melanoma: a phase II trial. J Interferon Cytokine Res. 2011 May; 31(5):433-40.
    View in: PubMed
    Score: 0.020
  17. Triozzi PL, Singh AD. Blood biomarkers of uveal melanoma metastasis. Br J Ophthalmol. 2011 Jan; 95(1):3-4.
    View in: PubMed
    Score: 0.020
  18. Triozzi PL, Aldrich W, Dombos C. Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo. Melanoma Res. 2008 Dec; 18(6):420-30.
    View in: PubMed
    Score: 0.017
  19. Triozzi PL, Eng C, Singh AD. Targeted therapy for uveal melanoma. Cancer Treat Rev. 2008 May; 34(3):247-58.
    View in: PubMed
    Score: 0.016
  20. Triozzi PL, Shah JJ, Wang WQ, Aldrich W, Edberg JC, Su K, Carlisle R, Conry R, LoBuglio AF, Forero A. Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity. Cancer Biother Radiopharm. 2006 Dec; 21(6):553-60.
    View in: PubMed
    Score: 0.015
  21. Triozzi PL, Bolger GB, Neidhart J, Rinehart JJ, Saleh M, Allen KO, Sellers S, Waddell MJ. Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer. Prostate. 2005 Dec 01; 65(4):316-21.
    View in: PubMed
    Score: 0.014
  22. Triozzi PL, Aldrich W, Allen KO, Carlisle RR, LoBuglio AF, Conry RM. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J Immunother. 2005 Jul-Aug; 28(4):382-8.
    View in: PubMed
    Score: 0.014
  23. Triozzi PL, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res. 2005 Jun 01; 11(11):4168-75.
    View in: PubMed
    Score: 0.014
  24. Triozzi PL, Strong TV, Bucy RP, Allen KO, Carlisle RR, Moore SE, Lobuglio AF, Conry RM. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum Gene Ther. 2005 Jan; 16(1):91-100.
    View in: PubMed
    Score: 0.013
  25. Ponnazhagan S, Mahendra G, Lima J, Aldrich WA, Jenkins CB, Ren C, Kumar S, Kallman L, Strong TV, Shaw DR, Triozzi PL. Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant. Hum Gene Ther. 2004 Sep; 15(9):856-64.
    View in: PubMed
    Score: 0.013
  26. Triozzi PL, Kim J, Aldrich W. Infusion of unpulsed dendritic cells derived from granulocyte/macrophage colony-stimulating factor-mobilized peripheral blood CD34+ cells and monocytes in patients with advanced carcinoma. J Hematother Stem Cell Res. 2003 Jun; 12(3):279-87.
    View in: PubMed
    Score: 0.012
  27. Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin Cancer Res. 2002 Jul; 8(7):2044-51.
    View in: PubMed
    Score: 0.011
  28. Helis CA, Hughes RT, Glenn CW, Lanier CM, Masters AH, Dohm A, Ahmed T, Ruiz J, Triozzi P, Gondal H, Cramer CK, Tatter SB, Laxton AW, Xing F, Lo HW, Su J, Watabe K, Wang G, Whitlow CT, Chan MD. Predictors of Adverse Radiation Effect in Brain Metastasis Patients Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):295-303.
    View in: PubMed
    Score: 0.010
  29. Votanopoulos KI, Forsythe S, Sivakumar H, Mazzocchi A, Aleman J, Miller L, Levine E, Triozzi P, Skardal A. Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study. Ann Surg Oncol. 2020 Jun; 27(6):1956-1967.
    View in: PubMed
    Score: 0.009
  30. Soike MH, Logue J, Qasem S, Hughes RT, McTyre E, Su J, Triozzi P, Bendandi M, Lo HW, Ahmed T, O'Neill SS, Debinski W, Pasche B, Watabe K, Miller LD, Chan MD, Ruiz J. CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery. Sci Rep. 2019 10 07; 9(1):14385.
    View in: PubMed
    Score: 0.009
  31. Binkley E, Triozzi PL, Rybicki L, Achberger S, Aldrich W, Singh A. A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes. Br J Ophthalmol. 2020 04; 104(4):524-528.
    View in: PubMed
    Score: 0.009
  32. Tafreshi NK, Tichacek CJ, Pandya DN, Doligalski ML, Budzevich MM, Kil H, Bhatt NB, Kock ND, Messina JL, Ruiz EE, Delva NC, Weaver A, Gibbons WR, Boulware DC, Khushalani NI, El-Haddad G, Triozzi PL, Moros EG, McLaughlin ML, Wadas TJ, Morse DL. Melanocortin 1 Receptor-Targeted a-Particle Therapy for Metastatic Uveal Melanoma. J Nucl Med. 2019 08; 60(8):1124-1133.
    View in: PubMed
    Score: 0.009
  33. Chesney J, Awasthi S, Curti B, Hutchins L, Linette G, Triozzi P, Tan MCB, Brown RE, Nemunaitis J, Whitman E, Windham C, Lutzky J, Downey GF, Batty N, Amatruda T. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma. Melanoma Res. 2018 02; 28(1):44-51.
    View in: PubMed
    Score: 0.008
  34. Bhatt NB, Pandya DN, Dezarn WA, Marini FC, Zhao D, Gmeiner WH, Triozzi PL, Wadas TJ. Practical Guidelines for Cerenkov Luminescence Imaging with Clinically Relevant Isotopes. Methods Mol Biol. 2018; 1790:197-208.
    View in: PubMed
    Score: 0.008
  35. Schuermeyer I, Maican A, Sharp R, Bena J, Triozzi PL, Singh AD. Depression, Anxiety, and Regret Before and After Testing to Estimate Uveal Melanoma Prognosis. JAMA Ophthalmol. 2016 Jan; 134(1):51-6.
    View in: PubMed
    Score: 0.007
  36. Crabb JW, Hu B, Crabb JS, Triozzi P, Saunthararajah Y, Tubbs R, Singh AD. iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors. PLoS One. 2015; 10(8):e0135543.
    View in: PubMed
    Score: 0.007
  37. Choudhary MM, Triozzi PL, Singh AD. Uveal melanoma: evidence for adjuvant therapy. Int Ophthalmol Clin. 2015; 55(1):45-51.
    View in: PubMed
    Score: 0.007
  38. Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, Selig S, Flaherty KT, Carvajal RD. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res. 2015 Mar; 28(2):135-47.
    View in: PubMed
    Score: 0.006
  39. Minca EC, Tubbs RR, Portier BP, Wang Z, Lanigan C, Aronow ME, Triozzi PL, Singh A, Cook JR, Saunthararajah Y, Plesec TP, Schoenfield L, Cawich V, Sulpizio S, Schultz RA. Genomic microarray analysis on formalin-fixed paraffin-embedded material for uveal melanoma prognostication. Cancer Genet. 2014 Jul-Aug; 207(7-8):306-15.
    View in: PubMed
    Score: 0.006
  40. Mittal K, Koon H, Elson P, Triozzi P, Dowlati A, Chen H, Borden EC, Rini BI. Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers. . 2014 Aug; 15(8):975-81.
    View in: PubMed
    Score: 0.006
  41. Joshi P, Jacobs B, Derakhshan A, Moore LR, Elson P, Triozzi PL, Borden E, Zborowski M. Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma. Oncotarget. 2014 May 15; 5(9):2450-61.
    View in: PubMed
    Score: 0.006
  42. Garcia JA, Elson P, Tyler A, Triozzi P, Dreicer R. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial. Urol Oncol. 2014 Jan; 32(1):33.e11-7.
    View in: PubMed
    Score: 0.006
  43. Singh AD, Aronow ME, Sun Y, Bebek G, Saunthararajah Y, Schoenfield LR, Biscotti CV, Tubbs RR, Triozzi PL, Eng C. Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array. Invest Ophthalmol Vis Sci. 2012 Jun 05; 53(7):3331-9.
    View in: PubMed
    Score: 0.006
  44. Aronow M, Sun Y, Saunthararajah Y, Biscotti C, Tubbs R, Triozzi P, Singh AD. Monosomy 3 by FISH in uveal melanoma: variability in techniques and results. Surv Ophthalmol. 2012 Sep; 57(5):463-73.
    View in: PubMed
    Score: 0.006
  45. Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, Sekeres M, Advani A, Tiu R, Reu F, Kalaycio M, Copelan E, Hsi E, Lichtin A, Bolwell B. p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol. 2012 Feb; 39(1):97-108.
    View in: PubMed
    Score: 0.005
  46. Yi T, Elson P, Mitsuhashi M, Jacobs B, Hollovary E, Budd TG, Spiro T, Triozzi P, Borden EC. Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects. Oncotarget. 2011 Dec; 2(12):1155-64.
    View in: PubMed
    Score: 0.005
  47. Schwandt A, Garcia JA, Elson P, Wyckhouse J, Finke JH, Ireland J, Triozzi P, Zhou M, Dreicer R, Rini BI. Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. J Clin Immunol. 2011 Aug; 31(4):690-8.
    View in: PubMed
    Score: 0.005
  48. Negrotto S, Hu Z, Alcazar O, Ng KP, Triozzi P, Lindner D, Rini B, Saunthararajah Y. Noncytotoxic differentiation treatment of renal cell cancer. Cancer Res. 2011 Feb 15; 71(4):1431-41.
    View in: PubMed
    Score: 0.005
  49. Torres V, Triozzi P, Eng C, Tubbs R, Schoenfiled L, Crabb JW, Saunthararajah Y, Singh AD. Circulating tumor cells in uveal melanoma. Future Oncol. 2011 Jan; 7(1):101-9.
    View in: PubMed
    Score: 0.005
  50. Garcia JA, Mekhail T, Elson P, Triozzi P, Nemec C, Dreicer R, Bukowski RM, Rini BI. Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU Int. 2011 Feb; 107(4):562-70.
    View in: PubMed
    Score: 0.005
  51. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res. 2009 Oct 01; 15(19):6277-83.
    View in: PubMed
    Score: 0.005
  52. Garcia JA, Klein EA, Magi-Galluzzi C, Elson P, Triozzi P, Dreicer R. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin Cancer Res. 2008 May 15; 14(10):3052-9.
    View in: PubMed
    Score: 0.004
  53. Forero A, Shah J, Carlisle R, Triozzi PL, LoBuglio AF, Wang WQ, Fujimori M, Conry RM. A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. Cancer Biother Radiopharm. 2006 Dec; 21(6):561-8.
    View in: PubMed
    Score: 0.004
  54. Korokhov N, de Gruijl TD, Aldrich WA, Triozzi PL, Banerjee PT, Gillies SD, Curiel TJ, Douglas JT, Scheper RJ, Curiel DT. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. . 2005 Mar; 4(3):289-94.
    View in: PubMed
    Score: 0.003
  55. Pereboev AV, Nagle JM, Shakhmatov MA, Triozzi PL, Matthews QL, Kawakami Y, Curiel DT, Blackwell JL. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol Ther. 2004 May; 9(5):712-20.
    View in: PubMed
    Score: 0.003
  56. Neidhart J, Allen KO, Barlow DL, Carpenter M, Shaw DR, Triozzi PL, Conry RM. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine. 2004 Jan 26; 22(5-6):773-80.
    View in: PubMed
    Score: 0.003
  57. Korokhov N, Mikheeva G, Krendelshchikov A, Belousova N, Simonenko V, Krendelshchikova V, Pereboev A, Kotov A, Kotova O, Triozzi PL, Aldrich WA, Douglas JT, Lo KM, Banerjee PT, Gillies SD, Curiel DT, Krasnykh V. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol. 2003 Dec; 77(24):12931-40.
    View in: PubMed
    Score: 0.003
  58. Belousova N, Korokhov N, Krendelshchikova V, Simonenko V, Mikheeva G, Triozzi PL, Aldrich WA, Banerjee PT, Gillies SD, Curiel DT, Krasnykh V. Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol. 2003 Nov; 77(21):11367-77.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.